Congress
Cost of Care for Relapsing/Remitting Multiple Sclerosis Treatments: A Pharmacoeconomic Evaluation from the Spanish Healthcare System Perspective

Cost of Care for Relapsing/Remitting Multiple Sclerosis Treatments: A Pharmacoeconomic Evaluation from the Spanish Healthcare System Perspective

Relapsing/remitting multiple sclerosis (RRMS) imposes a significant burden on patients and healthcare systems.

This study aimed to assess the pharmacoeconomic impact of 12 available treatment alternatives for RRMS in Spain, including fumarates, S1P receptor modulators, monoclonal antibodies, and immune reconstitution therapies, focusing on the total cost of care over a 4-year time horizon from the perspective of the Spanish National Healthcare System (NHS).

Authors: Caminero A, Romera M, Otero-Romero S, De Los Santos H, Alcalá B, Granado Y, Soler M, Arévalo A

Year: 2025

Congress: ISPOR


Download PDF Outside URL
Skip to content
Powered by  GDPR Cookie Compliance
Privacy Summary

This website uses cookies so that we can offer you the best possible user experience. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website or helping our team understand which sections of the website you find most interesting and useful.